首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1542912

全球抗菌藥物敏感性測試市場 - 2024-2031

Global Antimicrobial Susceptibility Testing Market - 2024-2031

出版日期: 2024年08月26日 | 出版商:

DataM Intelligence | 英文 200 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

抗菌藥物敏感性測試市場規模

2023年，全球抗菌藥物敏感性測試市場規模達3,46,754萬美元，預計2031年將達到5,4302億美元，2024-2031年預測期間複合年成長率為5.9%。

抗菌藥物敏感性測試 (AST) 是由醫療技術人員或臨床實驗室科學家進行的實驗室技術，用於確定哪種抗菌方案對個別患者特別有效。它在很大程度上有助於評估醫院、診所和國家傳染病管理和預防計畫提供的治療服務。

抗菌藥物敏感性測試市場動態

全球抗菌藥物敏感性測試市場的成長是由技術進步、傳染患者病率上升、政府和私人組織研發資金增加以及醫療基礎設施進步所推動的。

全球抗菌藥物敏感性測試需求的不斷成長推動了市場的成長

抗菌素抗藥性（AMR）已成為全球公共衛生的主要威脅。據世界衛生組織（WHO）稱，世界所有地區的抗生素抗藥性正在上升至危險的高水平，導致發病率和死亡率上升。此外，世界銀行估計，抗藥性感染可能引發全球經濟危機，到2050年每年可能有2,800萬人陷入極端貧困，每年造成全球經濟1兆美元的整體損失。

準確、快速地檢測抗菌藥物抗藥性並進行適當的抗菌治療，並結合抗菌藥物管理，對於控制抗菌素抗藥性的出現和傳播至關重要。治療細菌感染的最佳治療選擇依賴 AST 的結果，這是所有臨床微生物實驗室日常工作的一部分。報告提供了對當地抗菌藥物敏感性模式的了解，幫助醫療保健專業人員選擇最有效的抗生素治療。例如，如果病原體的 AMR 率高於 20%，則不應將該藥物作為感染治療的單一經驗療法。

此外，市場參與者正在採取收購和產品推出等市場策略。例如，2022 年 4 月，BIOMERIEUX 同意收購 Specific Diagnostics。這家總部位於美國的私人公司開發了一種快速抗菌藥物敏感性測試 (AST)，即 SPECIFIC REVEAL 快速 AST 系統，可直接從陽性血液培養物中提供表現型 AST。此外，2020 年 2 月，Bio-Rad Laboratories, Inc. 收購了 Exact Diagnostics，這是一家診斷產品開發商和製造商，有助於確保測試結果的有效性和一致性。透過收購 Exact Diagnostics，Bio-Rad Laboratories, Inc. 可以獲得移植、呼吸、病毒學、微生物學、性傳播感染和媒介傳播疾病領域的分子品質控制產品的全面目錄。

抗菌藥敏測試產品/儀器的缺點將阻礙市場的成長

然而，除了成本高之外，分子方法的主要缺點是僅透過可用探針來檢測抗性基因並高估抗性，因為抗性基因不一定與抗性表現型的表達相關。此外，自動化和半自動化系統具有固有的優勢和局限性，且結果因抗菌藥物、軟體版本和卡片的不同而差異很大。因此，一些系統對於正確地對某些藥物的敏感性概況進行分類是不可靠的，從而導致敏感性類別的錯誤分類。看來，小接種量會顯著影響這些系統的結果，並報告了錯誤的敏感性。

COVID-19對抗菌藥物敏感性測試市場的影響分析

在 COVID-19 大流行期間，與 AMR 合作夥伴合作的能力有限，導致資金減少，護理、醫療和公共衛生人員的可用性減少，影響了 AMR 的監測、預防和控制。根據臨床和實驗室標準研究所 (CLSI) 2020 年報告，迫切需要快速診斷來確定患者是否感染、確定病毒和細菌來源以及識別病原體及其敏感性特徵。實驗室可以透過快速識別可疑病原體並確定其對治療的敏感性，在快節奏的環境中指導首次正確的臨床決策。這不僅可以顯著改善個人結果，而且還可以避免不必要的抗生素使用。此外，預計未來幾年，消毒劑（包括洗手液和表面清潔劑）的使用增加將導致病原微生物的抗菌素抗藥性率上升。

抗菌藥物敏感性測試市場細分分析

自動化實驗室儀器領域預計在預測期內（2024-2031）將以最快的複合年成長率成長

依產品類型：

敏感性測試盤

麥克風條

磁敏感板

自動化實驗室儀器

耗材

按方法：

肉湯稀釋法

快速自動化方法

圓盤擴散法

梯度擴散法

分子檢測方法

按測試類型：

抗菌

抗真菌劑

抗寄生蟲藥

其他

按申請：

臨床診斷

藥物發現與開發

其他

按最終用戶：

診斷中心和醫院

製藥和生物技術公司

合約研究組織 (CRO)

研究和學術機構

自動化實驗室儀器領域佔據最大的市場。根據 2022 年《抗生素雜誌》上發表的文章，市場上現有快速 AST 技術，包括基於微量稀釋藥敏測試的自動化和半自動化設備。例如，Phoenix 系統被臨床微生物學實驗室廣泛接受並用於鑑定和抗菌藥物敏感性測試。確定敏感性的原理是基於使用氧化還原指示劑（阿拉瑪藍或刃天青染料）並檢測不同濃度抗菌劑存在下的細菌生長。此外，MicroScan WalkAway plus 系統可為各種革蘭氏陽性和革蘭氏陰性需氧細菌提供準確、快速的鑑定和藥敏結果。

此外，市面上第一代 MicroScan WalkAway 系統是 AutoSCAN-3。新版本的儀器 Auto-ACAN-4 和 AutoSCAN-WalkAway 進行了改進，並使用不需要冷藏的乾面板。 AutoSCAN-WalkAway 系統可偵測細菌酵素活性並可同時處理 96 個面板。先進的 AST 自動化系統的出現推動了全球市場的發展。

抗菌藥物敏感性測試市場地域佔有率

北美地區在全球抗菌藥物敏感性測試市場中佔有最大的市場佔有率

北美在抗菌藥物敏感性測試市場中佔據主導地位，預計在預測期內也將呈現類似的趨勢。北美抗菌藥物敏感性測試市場的成長可歸因於技術進步、傳染病的增加、產品上市的增加以及主要參與者的存在。

據生物梅里埃組織稱，美國每年發生超過 280 萬例抗生素抗藥性感染。抗藥性細菌的出現是一種不假裝的現象，抗生素使用不當會加劇和加速這種現象。該地區不斷增加的抗菌藥物敏感性測試推動了市場的發展。

此外，市場參與者正在採取收購和產品推出等市場策略。例如，2022 年 5 月，Accelerate Diagnostics, Inc. 宣布將其新型 Accelerate Arc 模組和 BC 套件商業化。 Accelerate Arc 模組和 BC 套件是在線離心和自動樣品製備技術的新應用，它與血液培養套件一起提供清潔的微生物細胞懸浮液，以便直接轉移到 MALDI 點樣板。此外，Accelerate PhenoTest BC 試劑盒 AST 配置使實驗室能夠直接報告陽性血液培養物的鑑定和抗菌藥物敏感性測試結果，比目前標準護理方法早幾天。

藥敏檢測企業及競爭格局

抗菌藥物敏感性測試市場是本地和全球公司的適度競爭的市場。為市場成長做出貢獻的一些主要參與者包括生物梅里埃公司、丹納赫公司、Becton、Dickinson and Company、Thermo Fisher Scientific Inc.、Bio-Rad Laboratories Inc.、默克集團、HiMedia Laboratories、Alifax Holding SpA、Creative Diagnostics 和共生等。主要參與者正在採取多種成長策略，例如產品發布、收購和合作，為全球抗菌藥物敏感性測試市場的成長做出貢獻。

例如，

2021 年 10 月，Thermo Fisher Scientific 和 Q-linea 推出了 AStar 技術，這是一種快速抗菌藥敏測試 (AST) 系統，可在 6 小時內提供真正的最低抑菌濃度 (MIC)資料。傳統的 AST 技術可能需要長達 72 小時才能獲得結果。

生物梅里埃公司

概述：

BioMerieux SA 是一家提供微生物學解決方案的組織，該解決方案用於臨床實驗室以提供有效的結果，因為診斷時間和治療效果對於感染控制、預防和管理多重抗藥性以及改善患者預後至關重要。

產品組合：

VITEK 2：它是一種自動化藥敏測試系統，能夠確定絕大多數常規微生物（約 300 種微生物）。由於分析軟體與原創的小型化消耗品相結合，因此該系統可在數小時內給出結果。此測試系統可用於各種微生物。

全球抗菌藥物敏感性測試市場報告將提供約 40 多個市場資料表、45 多個數字和 200 多個（大約）頁數。

Antimicrobial susceptibility testing (AST) is a laboratory technique conducted by medical technologists or clinical laboratory scientists to determine which antimicrobial regimen is particularly efficacious for individual patients. On an enormous scale, it helps evaluate treatment services delivered by hospitals, clinics, and national programs for managing and preventing infectious diseases.

Antimicrobial Susceptibility Testing Market Dynamics

The global antimicrobial susceptibility testing market growth is driven by technological advancement, a rising prevalence of infectious disease, rising funding for research and development from government and private organizations, and advancements in healthcare infrastructure.

The rising need for antimicrobial susceptibility testing across the globe drives the market growth

Antimicrobial resistance (AMR) has appeared as a major threat to public health worldwide. According to the World Health Organization (WHO), antibiotic resistance is rising to dangerously high levels in all regions of the world, leading to raised morbidity and mortality. In addition, the World Bank estimates that drug-resistant infections could induce a global economic crisis, leading to 28 million people who could be moved into extreme poverty every year by 2050, with an overall cost to the global economy of USD 1 trillion per year.

Exact and quick detection of resistance to antimicrobial drugs and following appropriate antimicrobial treatment, incorporated with antimicrobial stewardship, are crucial for controlling the emergence and spread of AMR. The best therapeutic option for treating bacterial infections relies on the results of AST, a part of the routine work of all clinical microbiological laboratories. Reports provide an understanding of local antimicrobial susceptibility patterns, helping healthcare professionals select the most effective antibiotic therapy. For instance, if the AMR rate of a pathogen is above 20%, that drug should not be administered as a single empiric therapy for infection treatment.

In addition, the market players are adopting the market strategies such as acquisition and product launches. For instance, in April 2022, BIOMERIEUX agreed to acquire Specific Diagnostics. This privately held U.S.-based company has developed a rapid antimicrobial susceptibility test (AST), SPECIFIC REVEAL Rapid AST system that delivers phenotypic AST directly from positive blood cultures. Moreover, in February 2020, Bio-Rad Laboratories, Inc. acquired Exact Diagnostics, a developer and manufacturer of diagnostic products that help ensure the validity and consistency of test results. With the acquisition of Exact Diagnostics, Bio-Rad Laboratories, Inc. has access to a comprehensive catalog of molecular quality control products in transplant, respiratory, virology, microbiology, sexually transmitted infections, and vector-borne diseases.

The drawbacks of antimicrobial susceptibility testing products/instruments will hamper the growth of the market

However, besides high costs, major drawbacks of molecular methods are the detection of the resistance genes targeted only by the available probes and overestimating resistance because the resistance gene is not necessarily associated with the expression of a resistance phenotype. In addition, automated and semi-automated systems have inherent advantages and limitations, and the results vary widely by antimicrobial drugs, software versions, and cards. Hence, some systems are unreliable for correctly categorizing susceptibility profiles for certain drugs, leading to wrong classifications of susceptibility categories. It appears that small inoculum size significantly influences the outcome of these systems, with false susceptibilities being reported.

COVID-19 Impact Analysis on Antimicrobial Susceptibility Testing Market

During the COVID-19 pandemic, the limited ability to work with AMR partnerships decreased funding, and reduced availability of nursing, medical, and public health staff affected AMR surveillance, prevention, and control. According to the Clinical and Laboratory Standards Institute (CLSI) 2020 report, there is a critical need for rapid diagnostics to determine if a patient has an infection, determine viral and bacterial sources, and identify the etiologic agent and its susceptibility profile. Labs can guide the right-first-time clinical decisions in fast-paced environments by fast identifying the suspected pathogen and determining its susceptibility to treatment. Not only can this significantly improve individual outcomes, but the approach also avoids unnecessary antibiotic use. In addition, increased use of disinfectants, including hand sanitizers and surface cleaners, is anticipated to cause inflated rates of antimicrobial resistance in pathogenic microbes in the coming years.

Antimicrobial Susceptibility Testing Market Segment Analysis

The automated laboratory instruments segment is expected to grow at the fastest CAGR during the forecast period (2024-2031)

By Product Type:

Susceptibility Testing Disks

MIC Strips

Susceptibility Plates

Automated Laboratory Instruments

Consumables

By Method:

Broth Dilution Method

Rapid Automated Method

Disk Diffusion Method

Gradient Diffusion Method

Molecular Testing Method

By Test Type:

Antibacterial

Antifungal

Antiparasitics

Others

By Application:

Clinical Diagnosis

Drug Discovery and Development

Others

By End-User:

Diagnostic Centers and Hospitals

Pharmaceutical and Biotechnology Companies

Contract Research Organizations (CROs)

Research and Academic Institutes

The automated laboratory instruments segment accounts for the largest market share. As per the article published in Antibiotics Journal in 2022, current technologies for rapid AST are available in the market, including automated and semi-automated devices based on microdilution susceptibility testing. For instance, the Phoenix System is widely accepted and used in clinical microbiology laboratories for identification and antimicrobial susceptibility testing. The principle of determining the susceptibility is based on using an oxidation-reduction indicator (Alamar blue or resazurin dye) and detecting bacterial growth in the presence of various concentrations of the antimicrobial agent. Also, The MicroScan WalkAway plus System provides accurate and rapid identification and susceptibility results for a wide range of Grampositive and Gram-negative aerobic bacteria.

In addition, The first generation of the MicroScan WalkAway System available on the market is the AutoSCAN-3. The new versions of instruments Auto-ACAN-4 and AutoSCAN-WalkAway are improved and use dry panels that do not need refrigeration. The AutoSCAN-WalkAway system detects bacterial enzymatic activity and can process 96 panels simultaneously. The availability of advanced and automated systems for AST boosts the market worldwide.

Antimicrobial Susceptibility Testing Market Geographical Share

North America region holds the largest market share of the global Antimicrobial Susceptibility Testing market

North America dominates the market for antimicrobial susceptibility testing and is expected to show a similar trend over the forecast period. The growth of the North American antimicrobial susceptibility testing market can be attributed to technological advancements, rising infectious disease, increasing launching of products and the presence of key players.

According to the bioMerieux organization, more than 2.8 million antibiotic-resistant infections occur annually in the United States. The emergence of resistant bacteria is an unpretending phenomenon worsened and accelerated by the improper use of antibiotics. Rising antimicrobial susceptibility testing in the region drives the market.

In addition, the market players are adopting the market strategies such as acquisition and product launches. For instance, in May 2022, Accelerate Diagnostics, Inc. announced the commercialization of its new Accelerate Arc Module and BC kit. The Accelerate Arc Module and BC kit is a new application of inline centrifugation and automated sample prep techniques, which, together with the blood culture kit, provides a suspension of cleaned microbial cells for direct transfer to a MALDI spotting plate. In addition, Accelerate PhenoTest BC kit AST configuration enables laboratories to report identification and antimicrobial susceptibility test results directly from positive blood cultures days earlier than current standard-of-care methods.

Antimicrobial Susceptibility Testing Companies and Competitive Landscape

The antimicrobial susceptibility testing market is a moderately competitive presence of local and global companies. Some of the key players contributing to the market's growth are bioMerieux S.A., Danaher Corporation, Becton, Dickinson and Company, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Merck Group, HiMedia Laboratories, Alifax Holding S.p.A., Creative Diagnostics, and Synbiosis, among others. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, contributing to the growth of the global antimicrobial susceptibility testing market.

For instance,

In October 2021, Thermo Fisher Scientific and Q-linea launched ASTar Technology, a quick antimicrobial susceptibility testing (AST) system that provides true minimum inhibitory concentration (MIC) data in less than 6 hours. Conventional AST techniques might take up to 72 hours to obtain findings.

bioMerieux SA

Overview:

bioMerieux SA is an organization that provides solutions for microbiology, which is used in clinical labs to provide effective results because time-to-diagnosis and therapeutic efficacy are paramount to infection control, preventing and managing multi-drug resistance and improving patient outcomes.

Product Portfolio:

VITEK 2: It is an automated susceptibility testing system capable of determining the extensive majority of routine organisms (around 300 microorganisms). This system gives results within hours due to the combination of analysis software and an original, miniaturized consumable. This testing system is available for a various range of microorganisms.

The global antimicrobial susceptibility testing market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

1. Market Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

4.1. Market Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising Prevalence of Infectious Diseases
  - 4.1.1.2. Technological Advancements
- 4.1.2. Restraints:
- 4.1.3. Strict Regulatory Procedures
- 4.1.4. Opportunity
- 4.1.5. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of Covid-19 on the Market
- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturer's Strategic Initiatives
6.6. Conclusion

7. By Product Type

7.1. Introduction
- 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
- 7.1.2. Market Attractiveness Index, By Product Type
7.2. Manual Antimicrobial Susceptibility Testing Products*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2023-2030
- 7.2.3. Susceptibility Testing Disks
- 7.2.4. MIC Strips
- 7.2.5. Susceptibility Plates
7.3. Automated Laboratory Instruments
7.4. Consumables

8. By Method

8.1. Introduction
- 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method
- 8.1.2. Market Attractiveness Index, By Method
8.2. Broth Dilution Method*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2023-2030
8.3. Rapid Automated Method
8.4. Disk Diffusion Method
8.5. Gradient Diffusion Method
8.6. Molecular Testing Method

9. By Test Type

9.1. Introduction
- 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
- 9.1.2. Market Attractiveness Index, By Test Type
9.2. Antibacterial*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2023-2030
9.3. Antifungal
9.4. Antiparasitics
9.5. Others

10. By Application

10.1. Introduction
- 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 10.1.2. Market Attractiveness Index, By Application
10.2. Clinical Diagnosis*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2023-2030
10.3. Drug Discovery and Development
10.4. Others

11. By End User

11.1. Introduction
- 11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 11.1.2. Market Attractiveness Index, By End User
11.2. Diagnostic Centers and Hospitals*
- 11.2.1. Introduction
- 11.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2023-2030
11.3. Pharmaceutical and Biotechnology Companies
11.4. Contract Research Organizations (CROs)
11.5. Research and Academic Institutes

12. By Region

12.1. Introduction
- 12.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2023-2030, By Region
- 12.1.2. Market Attractiveness Index, By Region
12.2. North America
- 12.2.1. Introduction
- 12.2.2. Key Region-Specific Dynamics
- 12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
- 12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method
- 12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
- 12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 12.2.8.1. The U.S.
  - 12.2.8.2. Canada
  - 12.2.8.3. Mexico
12.3. Europe
- 12.3.1. Introduction
- 12.3.2. Key Region-Specific Dynamics
- 12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
- 12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method
- 12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
- 12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 12.3.8.1. Germany
  - 12.3.8.2. U.K.
  - 12.3.8.3. France
  - 12.3.8.4. Italy
  - 12.3.8.5. Spain
  - 12.3.8.6. Rest of Europe
12.4. South America
- 12.4.1. Introduction
- 12.4.2. Key Region-Specific Dynamics
- 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
- 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method
- 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
- 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 12.4.8.1. Brazil
  - 12.4.8.2. Argentina
  - 12.4.8.3. Rest of South America
12.5. Asia Pacific
- 12.5.1. Introduction
- 12.5.2. Key Region-Specific Dynamics
- 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
- 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method
- 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
- 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 12.5.8.1. China
  - 12.5.8.2. India
  - 12.5.8.3. Japan
  - 12.5.8.4. Australia
  - 12.5.8.5. Rest of Asia Pacific
12.6. Middle East and Africa
- 12.6.1. Introduction
- 12.6.2. Key Region-Specific Dynamics
- 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
- 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method
- 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
- 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

13. Competitive Landscape

13.1. Key Developments and Strategies
13.2. Company Share Analysis
13.3. Product Benchmarking

14. Company Profiles

14.1. bioMerieux S.A.*
- 14.1.1. Company Overview
- 14.1.2. Product Portfolio and Description
- 14.1.3. Key Highlights
- 14.1.4. Financial Overview
14.2. Danaher Corporation
14.3. Becton, Dickinson and Company
14.4. Thermo Fisher Scientific Inc.
14.5. Bio-Rad Laboratories Inc.
14.6. Merck Group
14.7. HiMedia Laboratories
14.8. Alifax Holding S.p.A.
14.9. Creative Diagnostics
14.10. Synbiosis (*LIST NOT EXHAUSTIVE)